Alector Inc
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
ALEC$2.46+7.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
Exhibit Index
| Incorporated by Reference | ||||||
|---|---|---|---|---|---|---|
| Number | Exhibit Title | Form | File No. | Exhibit | FilingDate | FiledHerewith |
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant. | 8-K | 001-38792 | 3.1 | 2/11/2019 | |
| 3.2 | Amended and Restated Bylaws of the Registrant. | 8-K | 001-38792 | 3.1 | 6/15/2023 | |
| 4.2 | Specimen common stock certificate of the Registrant | S-1 | 333-229152 | 4.2 | 1/7/2019 | |
| 4.3 | Description of securities of the Registrant. | X | ||||
| 10.1+ | Form of Indemnification Agreement between the Registrant and each of its directors and executive officers. | S-1 | 333-229152 | 10.1 | 1/7/2019 | |
| 10.2+ | 2017 Stock Option and Grant Plan as amended and forms of agreement thereunder. | S-1 | 333-229152 | 10.2 | 1/7/2019 | |
| 10.3+ | 2019 Equity Incentive Plan and forms of agreements thereunder. | 10-K | 001-38792 | 10.3 | 2/27/2024 | |
| 10.4+ | 2019 Employee Stock Purchase Plan and form of agreement thereunder. | 10-K | 001-38792 | 10.4 | 2/27/2024 | |
| 10.5+ | 2022 Inducement Equity Incentive Plan, as amended, and forms of agreement thereunder. | 8-K | 333-229152 | 10.1 | 1//3/2022 | |
| 10.6+ | Confirmatory Offer Letter between the Registrant and Arnon Rosenthal, Ph.D. | S-1/A | 333-229152 | 10.5 | 1/29/2019 | |
| 10.7+ | Offer Letter dated November 30, 2021 by and between Alector, LLC and Saraswati (Sara) Kenkare-Mitra, Ph.D. | 10-K | 001-38792 | 10.18 | 2/24/2022 | |
| 10-8+ | Offer Letter dated February 4, 2022 by and between Alector, LLC and Marc Grasso, M.D. | 10-K | 001-38792 | 10.19 | 2/24/2022 | |
| 10.9+ | Offer Letter dated January 31, 2022 by and between Alector, LLC and Gary Romano, M.D., Ph.D. | 8-K | 001-38792 | 10.1 | 3/29/2022 | |
| 10.10+ | Executive Incentive Compensation Plan. | S-1 | 333-229152 | 10.10 | 1/7/2019 | |
| 10.11+ | Outside Director Compensation Policy. | 10-Q | 001-38792 | 10.2 | 5/8/2024 | |
| 10.12+ | Form of Change in Control and Severance Agreement between the Registrant and certain of its executive officers. | S-1 | 333-229152 | 10.12 | 1/7/2019 | |
| 10.13 | Lease between the Registrant and HCP Oyster Point III, LLC, dated June 27, 2018. | S-1 | 333-229152 | 10.14 | 1/7/2019 | |
| 10.14# | Third Amended and Restated Collaboration Agreement between the Registrant and Adimab, dated September 19, 2016, as amended. | S-1 | 333-229152 | 10.15 | 1/7/2019 | |
| 10.15# | Co-Development and Option Agreement between the Registrant and AbbVie Biotechnology, Ltd., dated October 16, 2017. | S-1 | 333-229152 | 10.16 | 1/7/2019 | |
| 10.16# | Collaboration and License Agreement, dated July 1, 2021, by and between Glaxo Wellcome UK Limited and Alector, Inc. | 10-Q | 001-38792 | 10.19 | 8/3/2021 | |
| 10.17# | Letter Agreement Amending the 2021 Collaboration and License Agreement between the Registrant and Glaxo Wellcome UK Ltd. dated May 19, 2023. | 10-Q | 001-38792 | 10.1 | 8/3/2023 | |
| 10.18# | Amendment Number One to Co-Development and Option Agreement between the Registrant and AbbVie Biotechnology Ltd., effective February 13, 2023. | 10-Q | 001-38792 | 10.1 | 5/4/2023 | |
| 10.19Δ | Sales Agreement, dated November 7, 2023, by and between Alector, Inc., and Cowen and Company, LLC | 8-K | 001-38792 | 1.1 | 11/7/2023 | |
| 10.20# | Letter Agreement Amending the 2021 Collaboration and License Agreement between the Registrant and Glaxo Wellcome UK Ltd. dated March 11, 2024. | 10-Q | 001-38792 | 10.1 | 5/8/2024 | |
| 10.21# | Loan and Security Agreement, dated as of November 14, 2024, among the Registrant and Alector LLC, as co-borrowers, the banks and financial institutions from time to time party thereto, and Hercules Capital, Inc., as administrative agent and collateral agent | X | ||||
| 10.22# | First Amendment to Loan and Security Agreement, dated December 12, 2024, by and among Alector Inc., Alector LLC, certain banks and other financial institutions, and Hercules Capital, Inc., as administrative agent and collateral agent | X | ||||
| 19 | Alector Inc. Insider Trading Policy | X | ||||
| 21.1 | List of subsidiaries of Registrant. | X | ||||
| 23.1 · Consent of Independent Registered Public Accounting Firm. · X | ||||||
|---|---|---|---|---|---|---|
| 31.1 · Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. · X | ||||||
| 31.2 · Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. · X | ||||||
| 32.1* · Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. · X | ||||||
| 32.2* · Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. · X | ||||||
| 97Δ | Compensation Recovery Policy | 10-K | 001-38792 | 97 | 2/27/2024 | |
| 101.INS | Inline XBRL Instance Document | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | X | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||
- Indicates management contract or compensatory plan.
Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission.
Δ Certain schedules and exhibits to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted exhibit or schedule will be furnished to the SEC or its staff upon request.
- The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.